Biomolecular events in cancer revealed by attractor metagenes
AssigneeThe Trustees of Columbia University in the City of New York
InventorsDimitris Anastassiou, Wei Yi Cheng
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions and methods for the independent and unconstrained identification of attractor metagenes as surrogates of pure biomolecular events as well as the use of such attractor metagenes in performing medical diagnosis, prognosis, and developing appropriate therapeutic regimes.
Claims15
A method for identifying an attractor from a data set, comprising:
- evaluating the data set, wherein the data set comprises information from a plurality of objects characterized by particular feature vectors and wherein said evaluation identifies, using a computer processor, an association between individual members of plurality of objects;
- and
- selecting, from the plurality of objects, a set of two or more objects maximally associated with a composite version of the same set of objects, and thereby identifying an attractor from said data set.
A system for identifying an attractor metagene from a gene data set, comprising:
- at least one processor and a computer readable medium coupled to the at least one processor, the computer readable medium having stored thereon instructions which when executed cause the processor to:
- evaluate the gene data set, wherein the gene data set comprises information from a plurality of genes and wherein said evaluation identifies, using the computer processor, an association between individual members of plurality of genes;
- and
- selecting, from the plurality of genes, a set of two or more genes maximally associated with a composite version of the same set of genes, and thereby identifying an attractor metagene from said gene data set.
A kit for detecting the presence of an attractor metagene comprising measuring means for one or more biomarker selected from the group consisting of the genes associated with an attractor metagene of FIG. 1A-B, Table 2, Table 3, or Table 4, where the measuring means is, for each biomarker to be measured, a pair of oligonucleotide primers capable of hybridizing the biomarker.
A method of treatment wherein a patient sample is assayed for the presence of one or more biomarker selected from the group consisting of the genes associated with an attractor metagene of FIG. 1A-B, Table 2, Table 3, or Table 4, and wherein, if said biomarker associated with the attractor metagene is present, thereafter adjusting said treatment accordingly.
A method of performing a prognosis of a subject wherein a patient sample is assayed for the presence of one or more biomarker selected from the group consisting of the genes associated with an attractor metagene of FIG. 1A-B, Table 2, Table 3, or Table 4, and wherein, if said biomarker associated with the attractor metagene is present, predicting the likely outcome of the cancer.
Dependencies are inferred from the claim text.